Baird raised the firm’s price target on Soleno Therapeutics (SLNO) to $102 from $72 and keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics price target raised to $105 from $75 at Laidlaw
- Soleno price target raised to $123 at Cantor Fitzgerald after VYKAT XR approved
- Soleno Therapeutics price target raised to $102 from $72 at Baird
- Aardvark Therapeutics price target raised to $26 from $22 at BofA
- Soleno Stock (SLNO) Soars 32% after FDA Greenlights New Drug